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Introduction
Hematopoietic stem cell transplantation (HSCT) 
has been used to treat a wide variety of malignant 
and non-malignant hematological disorders including 
leukemia, lymphomas, and aplastic anemia, and 
indications are expanding (Busca and Pagano., 2016). 
Invasive fungal infections (IFI) have become the leading 
cause of morbidity and mortality in bone marrow transplant 
(BMT) recipients (Fukuda et al., 2003; Kontoyiannis et 
al., 2010; Neofytos et al., 2009; Pagano et al., 2007). 
Reported risk factors are post-transplantation immune 
deficiency, immune suppression, high-dose steroids, 
neutropenia, viral infections, and acute graft-versus-host 
disease (GvHD) (Busca and Pagano., 2016; SteinbachWJ., 
2010; Zaoutis, 2010). 
Routinely four strategies including prophylactic, 
empiric, preemptive, and targeted therapy are applied 
for the management of fungal infections (Klepser, 2011). 
As a common practice, high risk patients receive 
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prophylaxis against fungal infections. As the use of 
antifungal prophylaxis is being increased, it becomes 
more important to define those patients most at risk for 
IFDs. For physicians faced with the challenge of selecting 
a systemically active oral antifungal, the principal choices 
are fluconazole, which lacks anti-mould activity, and 
the mould-active agents itraconazole, posaconazole, and 
voriconazole (Marks et al., 2011; Pechlivanoglou et al., 
2011). However, the optimum oral agent for antifungal 
prophylaxis in HSCT recipients post-transplant remains 
uncertain. 
It is shown that posaconazole, voriconazole, 
and micafungin, have reduced the incidence of 
IFI compared to fluconazole and itraconazole; posaconazole 
and voriconazole have also reduced transplant-related 
mortality significantly and the risk of proven/probable 
IFI compared to fluconazole and itraconazole (Bow et al., 
2015; Xu et al., 2013).
In our center, all patients with BMT received 
fluconazole as fungal prophylaxis until 2012 and after 
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2012, prophylaxis was based on the risk stratification and 
three anti-fungal therapies, fluconazole, voriconazole and 
posaconazole were administered as proper. In this study 
we aim to evaluate efficacy of the fungal prophylaxis 
protocols before and after 2012 on the incidence of IFI, 
mortality rate and clinical findings. 
Materials and Methods 
In this cross-sectional retrospective study, a total of 
376 patients (220 male and 156 female between 10-68 
years old) who underwent bone marrow transplantation 
in Taleghani Hospital, Tehran, Iran between July 2008 
and July 2015 were studied. Exclusion criteria were death 
prior to the initiation of fungal prophylaxis or the use of an 
antifungal regimen other than fluconazole, voriconazole 
and posaconazole. Patients were also excluded if 
the transplant was performed at an outside institution. 
The study protocol was approved by ethics committee of 
Tehran University of Medical Sciences. 
Baseline demographics, underlying disease, 
clinical factors, associated treatment, treatment-related 
adverse events, and survival and prior and concomitant 
medications, and concurrent medical events were collected 
from hospital clinical and research records on all patients. 
Laboratory findings including liver function tests were 
also recorded. 
Patients were classified into three risk groups; patients 
were considered high risk if they had history of invasive 
fungal infection, being smoker or opium abuser, AML or 
MDS as their underlying disease. Low risk group were 
patients who received autologous BMT without any of 
above mentioned risk factors and moderate risk group 
were patients no included in the low or high risk group.  
Patients were divided in to two groups; group one, 
were those who underwent transplantation between 
2008 and 2012 and received fluconazole as antifungal 
prophylaxis and second group were those patients with 
transplantation between 2012 and 2015 and received 
antifungal prophylaxis (fluconazole, voriconazole 
and posaconazole) according their risk of fungal 
infection. This group was administered voriconazole, 
posaconazole and amphotericin B prophylaxis (high risk), 
voriconazole and amphotericin b prophylaxis (moderate 
risk) and fluconazole prophylaxis (low risk). The doses of 
anti-fungal drugs were as follows: cap fluconazole 100 mg 
twice daily, tab voriconazole 200 mg twice daily, syrup 
posaconazole 200 mg three times a day and amphotericin 
b 25 mg intravenously daily. 
Invasive fungal infection (IFI) has been redefined 
as invasive fungal disease (IFD) by the EORTC/MSG 
Consensus Group (2008). IFI is defined into three 
different categories; possible, probable and proven based 
on a combination of host factors, clinical criteria and 
mycological criteria (De Pauw et al., 2008). Patients 
were considered non-probable infection if it did not met 
criteria of above mentioned categories. 
Statistical analysis
All data were analyzed using SPSS20 (version 20; 
SPSS Inc., Chicago, IL). Results are expressed as Mean 
± standard deviation or percentage. The chi-squared 
and fisher exact tests were used to compare categorical 
variables and the Mann–Whitney U-test and independent 
t-test to compare continuous variables. p values of less 
than 0.05 were considered statistically significant. 
Results
Pre-transplant hematological diseases of the patients 
included multiple myeloma in 137 cases (36.5%), Hodgkin 
lymphoma in 106 cases (28.2%), non-Hodgkin lymphoma 
in 54 (14.2%), AML in 39 (10.4%), ALL in 23 (6.1%) and 
solid tumors including PNET, germ cell tumor in 17 cases 
(4.6%). Autologous and alogen transplant was performed 
in 310 (82.4%) and 66 (17.6%), respectively.
Of 376 patients, 206 (54.8%) were in group one and 
170 (45.2%) were in group two. Patients’ baseline findings 
are shown in Table 1. Group I was significantly younger, 
less smoker, received more autologus transplant and 
mostly high risk patient for infection.
Probable/proven IFI occurred in 27 (7.18%) of 
all BMT cases; possible infection was observed in 
128 (34%) of cases. Table 2 demonstrates the fungal 
infection findings between groups. Group I had significantly 
higher duration of fever and increased WBC, longer 
length of stay, more proven and probable fungal infections 
and higher hepatic complications. There was two deaths 
related to fungal infection, both occurred in group I. 
Three deaths in group I and 4 deaths in group II occurred 
due to non-fungal causes. In allogenic transplant patients 
acute GVHD and sepsis due to non-fungal infections and 
Group I Group II P value
Age (years) 37.18±14.1 41.07±13.5 0.007
Gender, male/female 123/83 97/73 0.6
Smoking 7 (3.4%) 17 (10%) 0.01
Opium use 1 (0.5%) 5 (2.9%) 0.09
Pulmonary disease 10 (4.9%) 4 (2.4%) 0.28
Transplant type
   Autologous 184 (89.3%) 129 (75.9%) 0.001
   Allogeneic 22 (10.7%) 41 (24.1%)
Underlying disease <0.001
   Lymphoma 115 (55.8%) 48 (28.2%)
   Multiple myeloma 63 (30.6%) 75 (44.1%)
   Acute Myeloid Leukemia 14 (6.8%) 25 (14.7%)
   Acute Lymphoblastic Leukemia 7 (3.4%) 16 (9.4%)
   Solid Tumors 7 (3.4%) 7 (3.5%)
Prophylaxis -----
   Fluconazole 206 (100%) 89 (52.4%)
   Voriconazole --- 30 (17.6%)
   Posaconazole --- 27 (15.9%)
   Amphotericin --- 6 (3.5%)
   Combination therapy --- 18 (10.6%)
Infection risk
   Low risk 24 (11.7%) 92 (54.1%) <0.001
   Moderate risk 19 (9.2%) 30 (17.6%)
   High risk 163 (79.1%) 48 (28.2%)
Table 1. Patients’ Baseline Findings
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itraconazole and 4% amphotericin B for prophylaxis and 
6% did not receive any antifungal agent for this purpose. 
Similarly, in our study, most patients received fluconazole, 
then voriconazole and posaconazole. 
Fluconazole is the most used and accepted antifungal 
treatment with more cost-benefit and cost-effectiveness. 
Previous studies have shown the significant efficacy of 
fluconazole prophylaxis. Ziakas et al., (2014) in their 
meta-analysis reported that patients receiving fluconazole 
compared to placebo accompanies with reduced risk of IFI, 
systemic candidiasis and the need for empiric antifungal 
treatment. 
Nowadays, the antifungal agent of choice for 
the prophylaxis of invasive fungal infection is a triazole 
(voriconazole or posaconazole) (Fleming et al., 2014; 
Marks et al., 2011; Soysal., 2015; Ullmann et al., 2007). 
Different studies have tried to compare the efficacy of 
these new agents with fluconazole. Wingard et al., (2010) 
compared voriconazole with fluconazole in allogeneic 
HSCT recipients. There was no difference in the 
incidence of proven-probable or presumptive IFI between 
two treatments; but the incidence of aspergillosis was 
marginally reduced in patients who received voriconazole. 
Posaconazole was also compared with fluconazole 
for prophylaxis of IFI (Ullmann et al., 2007). Although 
the incidence of IFI was higher in fluconazole, but the 
difference was not significant between groups, but deaths 
due to IFI was higher in fluconazole group.
In our study, we observed no significant difference 
between fluconazole with voriconazole and posaconazole 
groups regarding probable/possible IFI rate. Fluconazole 
group compared to risk-base treatment received more 
autologus transplant and were mostly high risk patient for 
IFI. They also had longer duration of fever, longer length of 
stay, more proven and less probable fungal infections and 
higher hepatic complications. But the difference between 
treatments in cumulative sum of proven/probable cases 
was not significant. There was no significant difference in 
fungal related and overall mortality rate between groups.
In order to choose proper antifungal drugs with better 
treatment efficacy, we need to understand the exact 
pharmacokinetics of each drug including the interaction of a 
drug with the host, measurements of absorption, distribution, 
metabolism and elimination which will help in choosing 
most efficacious and safe dose and interval of administration 
for a particular pathogen and infection site. Amphotericin 
B is eliminated by bile and kidney and is contraindicated in 
reversible renal impairment but could be used with no dose 
adjustment in hepatic impairment. Dose adjustment should 
be considered for fluconazole in renal impairment and for 
voriconazole in hepatic impairment while posaconazole 
needs no dose adjustment in renal or hepatic impairment. 
We should also consider the drug-drug interactions of 
these antifungal drugs; both fluconazole and voriconazole 
are strong inhibitors of CYP3A4 and 2C9. These drugs 
can decrease the availability of some drugs and so increase 
their efficacy and possible side effects (Bellmann and 
Smuszkiewicz, 2017).
Considering the high costs of new agents and low 
tolerance rate, voriconazole and posaconazole, it is better 
in autologous patients, also non fungal sepsis was the 
most common cause of death.
Probable/proven IFI was seen in 23 (7.8%) of patients 
with fluconazole prophylaxis, 2 (6.7%) of voriconazole 
prophylaxis and 1 (3.7%) of posaconazole prophylaxis. 
There was no significant difference between fluconazole 
and other two groups in infection rate.
Discussion
In this study, we evaluated the rate of IFI in patients 
receiving fluconazole regardless of their risk category 
with patients receiving the regimes based on the patient’s 
risk of IFI. We observed probable/proven IFI in 7.18% 
and possible infection in 34% of all BMT patients. This 
is higher than reported prevalence in other studies. 
In a study of United States tertiary care centers, overall 
incidence of proven/probable IFD was 3.4% (range, 
.9% to 13.2%) (Kontoyiannis et al., 2010). This is also 
reported by other large and small studies (Kurosawa et 
al., 2012; Pagano et al., 2007). 
However, similar to our findings, in a large study 
in China, the overall incidence of proven or probable 
IFD was 7.7% (Sun et al., 2015). They indicated that 
insufficient use of prophylaxis in these patients, especially 
high risk patients, was associated with an increased 
incidence of IFD. Furthermore, fluconazole was mostly 
used and for a shorter duration than recommended 
which has suboptimal efficacy compared with newer 
agents. All our patients received antifungal prophylaxis 
regardless of their risk category. Fluconazole was also 
used as the most common prophylaxis. 
Varieties of antifungal agents are now used for 
prophylaxis in different centers. Martino et al., (2002) 
reported that 73% of patients received fluconazole, 17% 
Table 2. The Fungal Infection Findings between Groups
Group I Group II P value
Fever duration (days) 4.7±0.26 3.2±0.66 0.004
Increased white blood cell 
duration (days) 13.47±6.3 12.12±4.9 0.02
Length of stay (days) 31.72±10.75 27.94±10.12 0.001
Empirical amphotericin use 29 (14.1%) 23 (13.5%) 0.88
Duration of empirical 
amphotericin use (days) 10.35±9.05 8.68±7.71 0.45
Galactomannan antigen 15 (7.3%) 8 (4.7%) 0.39
Imaging indicative of fungal 
infection 10 (4.9%) 6 (3.5%) 0.52
Invasive fungal infection
     Non-probable 130 (63.1%) 131 (77.1%) 0.008
     Possible 61 (29.6%) 27 (15.9%)
     Probable 12 (5.8%) 11 (6.5%)
     Proven 3 (1.5%) 1 (0.5%)
Hepatic complication grade
     0 116 (56.3%) 95 (55.9%) 0.003
     1 61 (29.6%) 67 (39.4%)
     ≥2 29 (14.1%) 8 (4.7%)
Death due to fungal infection 2 (1%) 0 ---
Death with no fungal infection 3 (1.5%) 4 (2.4%) 0.7
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to use these agents in high risk patients. Fluconazole 
is well-tolerated and less expensive and could be 
used for prophylaxis in most centers. As there was no 
significant difference among our patients with three 
different prophylaxis (fluconazole, voriconazole and 
posaconazole), it seems rationale to use fluconazole 
as the first choice of prophylaxis. However, that risk 
stratification may improve the proper use of antifungal 
prophylactic agents and reduce the possible costs. 
In conclusion, the use of prophylaxis based on risk of 
fungal infection in patients undergoing BMT results in 
reduced duration of fever and accelerates the engraftment 
and patient discharge. We found no significant difference 
regarding IFI rate between prophylaxis groups. 
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